V1RC12 Inhibitors
V1RC12 inhibitors represent a class of molecules engineered to engage with specific molecular pathways through the inhibition of the V1RC12 protein function. The V1RC12 protein belongs to a broader group of proteins that are involved in various biochemical processes within organisms. These proteins have distinct binding sites that can be targeted by inhibitors, which are compounds that can attach to these sites and modulate the protein's activity. The inhibitors in this chemical class are designed with high specificity to the V1RC12 protein, which is achieved through the careful arrangement of atoms and functional groups that match the unique topography of the protein's binding site.
The development of V1RC12 inhibitors involves intricate chemical synthesis and an in-depth understanding of molecular dynamics. These molecules often emerge from rigorous structure-activity relationship studies, wherein chemists iteratively modify parts of the molecule to enhance its interaction with the V1RC12 protein. The molecular structure of a V1RC12 inhibitor is typically complex, incorporating a variety of chemical motifs such as rings and chains, which are organized in a specific three-dimensional shape. This structural complexity enables the inhibitor to form multiple types of non-covalent bonds with the V1RC12 protein, including hydrogen bonding, hydrophobic interactions, and van der Waals forces. Additionally, the physicochemical characteristics of these inhibitors, like their solubility and stability, are optimized to ensure that they can effectively engage with the V1RC12 protein in its native environment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. By inhibiting EGFR, it can downregulate the PI3K/AKT pathway, which is crucial for the survival and proliferation of many cell types. If V1RC12 is downstream of this pathway, Erlotinib would lead to the functional inhibition of V1RC12 by curbing the necessary signals for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTORC1 signaling pathway, which is involved in cell growth and proliferation. This inhibition can reduce the activity of downstream proteins that are regulated by mTORC1 signaling, potentially including V1RC12 if it is regulated by this pathway. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that impedes the MEK1/2 and thus the MAPK/ERK signaling pathway. If V1RC12 activity is modulated by the MAPK/ERK pathway, Trametinib will indirectly reduce V1RC12's function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a tyrosine kinase inhibitor that targets several enzymes, including VEGFR, PDGFR, and RAF kinases. By inhibiting these kinases, Sorafenib can hinder angiogenesis and cell proliferation pathways that might be necessary for the functional activity of V1RC12. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor that prevents cell cycle progression. If V1RC12 is involved in cell cycle regulation, its activity could be diminished by the inhibition of these kinases. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that affects the degradation of proteins. If V1RC12 requires proteasome activity for its stability or function, Bortezomib could lower its activity by preventing its proper turnover. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can inhibit the JNK signaling pathway. Since JNK is involved in responses to stress and apoptosis, inhibition of this pathway could decrease the functional activity of V1RC12 if it is a part of stress response signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents the phosphorylation and activation of AKT, thereby affecting the PI3K/AKT pathway. If V1RC12 is regulated by or dependent on this pathway, LY294002 would lead to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that blocks the PI3K/AKT pathway. It would similarly decrease V1RC12's activity if V1RC12 signaling is PI3K/AKT-dependent. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a BCR-ABL tyrosine kinase inhibitor that also inhibits SRC family kinases. This inhibition can alter multiple signaling pathways including those involved in cell migration and survival, potentially reducing the functional activity of V1RC12. | ||||||